Clinical research
Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus
			
	
 
More details
Hide details
	
	
													
				
				
		
		
			
			
			
			 
			Submission date: 2010-05-25
			 
		 		
		
			
			 
			Final revision date: 2010-07-29
			 
		 		
		
		
			
			 
			Acceptance date: 2010-08-26
			 
		 		
		
			
			 
			Online publication date: 2011-11-08
			 
		 		
		
			
			 
			Publication date: 2011-11-08
			 
		 			
		 
	
							
																								
		
	 
		
 
 
Arch Med Sci 2011;7(5):864-869
		
 
 
KEYWORDS
TOPICS
ABSTRACT
 Introduction:  Systemic lupus erythematosus (SLE) is a complex, multifactor autoimmune disease. The studies on aetiopathogenesis of autoimmune diseases focus on the impact the genetically conditioned impairment of xenobiotic metabolism may exert. The knowledge of oxidation polymorphism in the course of SLE may be helpful in choosing more efficient and safer therapy. We determined whether there was an association between susceptibility to SLE and particularly to  CYP2D6  genotypes.  
 Material and methods : The study was carried out in 60 patients with SLE and 129 healthy volunteers and all the subjects were of Polish origin. The samples were analysed for two major defective alles for  CYP2D6 – CYP2D6*3  and  CYP2D6*4  and one wild -type allele  CYP2D6*1  -by the polymerase chain reaction fragment length polymorphism (PCR-RFLP) metod with DNA extracted from peripheral blood. 
 Results : No statistically significant differences in the incidence of  CYP2D6  genotypes between the studied groups were found (p = 0.615). Risk (OR) of SLE development was 1.03 for the carriers of  CYP2D6*3  allele and 1.48 for the subjects with  CYP2D6*4  allele; but it was not statistically significant.  
 Conclusions : Increased occurrence of mutant alleles of the  CYP2D6  gene in SLE patients and the calculated OR values could suggest the effect of these mutations on increased SLE development.